ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Br…

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...
Zacks.com on MSN

4 Medical Device Stocks to Buy for Healthy Returns in 2026

2025 brought ups and downs for the MedTech industry. Under President Trump’s second term, shifting trade policies, including new and heightened threats of tariffs, sanctions and other restrictions, ...